StudyFormycon successfully completes patient enrollment for the clinical development of its Keytruda® biosimilar candidate FYB206 10.07.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Lupin & Zentiva ink licensing and supply agreement for commercializing biosimilar Certolizumab Pegol: Our Bureau, Mumbai Wednesday, July 9, 2025, 16:20 Hrs [IST] Global Pharma maj ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the expansion of its capacity for ...

It is indicated for various diseases including heumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic ...

Under the terms of the agreement, Lupin will be responsible for the development, manufacturing, and supply of the product within the agreed territories. Zentiva will handle commercialization ...

President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...

The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

As investors await the opening of Anthem Biosciences IPO, here are the key strengths and risks outlined in its Red Herring ...

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 ...